ARCH Healthcare Fund
1
34M
2
- Stages of investment
- Areas of investment
Summary
The usual things for fund are deals in the range of 50 - 100 millions dollars. The high activity for fund was in 2010. The fund is constantly included in less than 2 deals per year.
The typical case for the fund is to invest in rounds with more than 10 participants. Despite the ARCH Healthcare Fund, startups are often financed by Vertex Ventures HC, Vertex Ventures, New Enterprise Associates. The meaningful sponsors for the fund in investment in the same round are Windham Venture Partners, Vertex Ventures HC, Vertex Ventures. In the next rounds fund is usually obtained by Kohlberg Kravis Roberts.
The fund has no exact preference in some founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular fund investment industries, there are Life Science, Medical Device. Among the most popular portfolio startups of the fund, we may highlight Earlens Corporation, Arbor Pharmaceuticals.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Investments by industry
- Biotechnology (1)
- Life Science (1)
- Pharmaceutical (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2010
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Arbor Pharmaceuticals | 11 Nov 2010 | Biotechnology, Life Science, Pharmaceutical | Early Stage Venture | 34M | United States, Atlanta, Georgia |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.